AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Columbus Macro LLC

Columbus Macro LLC raised its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 61.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 32,692 shares of the company’s stock after acquiring an additional 12,454 shares during the quarter. Columbus Macro LLC’s holdings in AstraZeneca were worth $2,142,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Stratos Wealth Advisors LLC lifted its position in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares in the last quarter. Crumly & Associates Inc. grew its stake in shares of AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares in the last quarter. Diversify Wealth Management LLC increased its position in shares of AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after acquiring an additional 153 shares during the period. Veery Capital LLC raised its stake in shares of AstraZeneca by 4.7% in the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after acquiring an additional 157 shares in the last quarter. Finally, Harbour Investments Inc. boosted its holdings in AstraZeneca by 1.9% in the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after purchasing an additional 160 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 1.3 %

NASDAQ AZN opened at $69.86 on Tuesday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a market capitalization of $216.64 billion, a price-to-earnings ratio of 33.43, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. The company’s fifty day moving average price is $67.08 and its two-hundred day moving average price is $73.85.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the firm posted $0.87 EPS. As a group, research analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.